Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 4:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 585 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease, Interstitial Lung Disease, Amyotrophic Lateral Sclerosis, End Stage Liver Disease, End Stage Renal Disease, Diabetes Complications
Interventions
Respecting Choices First Steps, Five Wishes Form
Behavioral
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Columbia, South Carolina + 1 more
Conditions
Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Interventions
BI 770371, Placebo for BI 770371
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Coronado, California • Montclair, California + 8 more
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Psoriasis, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
MT-7117 low dose, MT-7117 high dose, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
Interventions
Quantitative ultrasound (DeepUSFF)
Device
Lead sponsor
Seoul National University Hospital
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boardman, Ohio
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Stromal Tumor, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Meningeal Chronic Myelogenous Leukemia, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
Interventions
imatinib mesylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Wilson Disease
Interventions
UX701, Standard of Care (SOC)
Genetic · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • Sacramento, California + 9 more
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Obesity, Obesity (Body Mass Index >30 kg/m2)
Interventions
Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
Device · Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
Interventions
Sitagliptin
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

NCT04537377
Conditions
Wilson's Disease
Interventions
VTX-801
Genetic
Lead sponsor
Vivet Therapeutics SAS
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
6
States / cities
Sacramento, California • New Haven, Connecticut • Orlando, Florida + 3 more
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
DISC-1459
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
12 Years and older
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Detroit, Michigan + 5 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Implementing Food Referrals for Equity and Sustained Health

NCT06661538
Conditions
Food Insecurity
Interventions
Food Security Screening & Referral Program
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
5 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Conditions
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Hepatic Encephalopathy
Interventions
Critical flicker frequency
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
NAFLD, Obesity, Nutritional and Metabolic Diseases
Interventions
Time restricted eating
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Davis, California
Completed Not applicable Interventional Accepts healthy volunteers

High Fructose Corn Syrup

NCT02018237
Conditions
Nonalcoholic Fatty Liver Disease, Obesity
Interventions
High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts